| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.75 [0.65, 0.86] | | < 1 | | 62% | 10 studies (10/-) | 100.0 % | low | low | high | crucial | - |
| deaths (OS) (extension) | 0.66 [0.57, 0.77] | | < 1 | | 58% | 5 studies (5/-) | 100.0 % | low | not evaluable | high | important | - |
| MFS | 0.73 [0.56, 0.96] | | < 1 | | 0% | 1 study (1/-) | 98.8 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.55 [0.45, 0.67] | | < 1 | | 80% | 6 studies (6/-) | 100.0 % | low | not evaluable | high | important | - |
| progression or deaths (PFS) | 0.64 [0.51, 0.80] | | < 1 | | 82% | 8 studies (8/-) | 100.0 % | low | not evaluable | high | important | - |
| RFS (extension) | 0.71 [0.59, 0.85] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| RFS/DFS | 0.57 [0.37, 0.87] | | < 1 | | 41% | 2 studies (2/-) | 99.5 % | low | not evaluable | high | important | - |
| DCR | 1.06 [0.82, 1.37] | | > 1 | | 10% | 2 studies (2/-) | 67.5 % | low | not evaluable | high | non important | - |
| objective responses (ORR) | 2.49 [1.39, 4.46] | | > 1 | | 93% | 9 studies (9/-) | 99.9 % | low | not evaluable | high | non important | - |
| objective responses (ORR) (extension) | 5.60 [3.83, 8.17] | | > 1 | | 65% | 4 studies (4/-) | 100.0 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
| AE (any grade) | 2.25 [0.33, 15.15] | | < 1 | | 87% | 3 studies (3/-) | 20.4 % | low | not evaluable | high | non important | - |
| AE (grade 3-4) | 1.03 [0.21, 5.01] | | < 1 | | 98% | 3 studies (3/-) | 48.6 % | low | not evaluable | high | non important | - |
| AE leading to death (grade 5) | 1.35 [0.44, 4.13] | | < 1 | | 0% | 2 studies (2/-) | 29.8 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.25 [0.02, 89.58] | | < 1 | | 99% | 2 studies (2/-) | 46.0 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 1.09 [0.01, 103.30] | | < 1 | | 98% | 2 studies (2/-) | 48.6 % | low | not evaluable | high | non important | - |
| SAE (any grade) | 3.69 [1.68, 8.08] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| SAE (grade 3-4) | 3.48 [1.58, 7.66] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 1.26 [0.42, 3.80] | | < 1 | | 91% | 3 studies (3/-) | 34.1 % | some concern | not evaluable | moderate | non important | - |
| STRAE (grade 3-4) | 4.03 [1.73, 9.38] | | < 1 | | 0% | 3 studies (3/-) | 0.1 % | low | not evaluable | high | non important | - |
| TRAE (any grade) | 1.55 [0.94, 2.54] | | < 1 | | 88% | 10 studies (10/-) | 4.2 % | low | low | high | non important | - |
| TRAE (grade 3-4) | 1.61 [0.76, 3.40] | | < 1 | | 97% | 10 studies (10/-) | 10.6 % | low | low | high | non important | - |
| TRAE leading to death (grade 5) | 1.18 [0.40, 3.47] | | < 1 | | 0% | 8 studies (8/-) | 38.2 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (any grade) | 1.69 [0.68, 4.23] | | < 1 | | 97% | 9 studies (9/-) | 13.1 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 1.66 [0.58, 4.75] | | < 1 | | 96% | 9 studies (9/-) | 17.3 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.58 [0.18, 1.87] | | < 1 | | 0% | 8 studies (8/-) | 81.9 % | low | not evaluable | high | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 2.06 [0.07, 62.55] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 1.48 [0.67, 3.29] | | < 1 | | 0% | 8 studies (8/-) | 16.7 % | low | not evaluable | high | non important | - |
| Alopecia TRAE (grade 3-4) | 0.95 [0.10, 9.21] | | < 1 | | 0% | 3 studies (3/-) | 51.6 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 1.34 [0.24, 7.35] | | < 1 | | 0% | 3 studies (3/-) | 36.9 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 1.00 [0.34, 3.00] | | < 1 | | 0% | 8 studies (8/-) | 49.7 % | low | not evaluable | high | non important | - |
| Asthenia TRAE (grade 3-4) | 0.43 [0.16, 1.15] | | < 1 | | 0% | 7 studies (7/-) | 95.3 % | low | not evaluable | high | non important | - |
| Blood and lymphatic system disorders TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Chills TRAE (grade 3-4) | 0.81 [0.11, 5.75] | | < 1 | | 0% | 4 studies (4/-) | 58.5 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 0.94 [0.41, 2.18] | | < 1 | | 83% | 9 studies (9/-) | 55.7 % | low | not evaluable | high | non important | - |
| Constipation TRAE (grade 3-4) | 0.94 [0.11, 8.13] | | < 1 | | 0% | 3 studies (3/-) | 52.1 % | some concern | not evaluable | moderate | non important | - |
| Cough TRAE (grade 3-4) | 0.98 [0.23, 4.22] | | < 1 | | 0% | 6 studies (6/-) | 51.2 % | low | not evaluable | high | non important | - |
| Decreased appetite TRAE (grade 3-4) | 1.85 [0.55, 6.30] | | < 1 | | 0% | 7 studies (7/-) | 16.2 % | low | serious | high | non important | - |
| Diabetes TRAE (grade 3-4) | 1.24 [0.17, 8.83] | | < 1 | | 0% | 3 studies (3/-) | 41.6 % | low | not evaluable | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.88 [0.47, 1.65] | | < 1 | | 79% | 10 studies (10/-) | 65.4 % | low | low | high | non important | - |
| Dizziness TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Dry skin TRAE (grade 3-4) | 1.29 [0.63, 2.67] | | < 1 | | 0% | 6 studies (6/-) | 24.3 % | low | serious | high | non important | - |
| Dysgeusia TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Dyspepsia TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 1.94 [0.63, 6.00] | | < 1 | | 0% | 7 studies (7/-) | 12.6 % | low | not evaluable | high | non important | - |
| Ear and labyrinth disorders TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 1.31 [0.39, 4.40] | | < 1 | | 66% | 4 studies (4/-) | 33.3 % | low | not evaluable | high | non important | - |
| Eye disorders TRAE (grade 3-4) | 1.01 [0.09, 11.20] | | < 1 | | 0% | 2 studies (2/-) | 49.8 % | low | not evaluable | high | non important | - |
| Fatigue TRAE (grade 3-4) | 1.59 [0.74, 3.42] | | < 1 | | 32% | 8 studies (8/-) | 11.8 % | low | not evaluable | high | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Gastritis TRAE (grade 3-4) | 4.19 [0.18, 95.03] | | < 1 | | 0% | 1 study (1/-) | 18.7 % | NA | not evaluable | | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 1.06 [0.28, 4.07] | | < 1 | | 93% | 5 studies (5/-) | 46.4 % | low | not evaluable | high | non important | - |
| General disorders and administration site conditions TRAE (grade 3-4) | 4.19 [0.18, 95.03] | | < 1 | | 0% | 1 study (1/-) | 18.7 % | NA | not evaluable | | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Headache TRAE (grade 3-4) | 0.82 [0.28, 2.36] | | < 1 | | 0% | 8 studies (8/-) | 64.6 % | low | not evaluable | high | non important | - |
| Hepatitis TRAE (grade 3-4) | 3.26 [1.50, 7.12] | | < 1 | | 0% | 9 studies (9/-) | 0.1 % | low | not evaluable | high | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 2.30 [0.16, 33.53] | | < 1 | | 89% | 4 studies (4/-) | 27.4 % | low | not evaluable | high | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 3.72 [0.39, 35.19] | | < 1 | | 0% | 2 studies (2/-) | 12.8 % | low | not evaluable | high | non important | - |
| Hypertension TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.74 [0.55, 5.45] | | < 1 | | 0% | 8 studies (8/-) | 17.2 % | low | not evaluable | high | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.65 [0.34, 1.23] | | < 1 | | 21% | 10 studies (10/-) | 90.7 % | low | low | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.03 [0.35, 3.03] | | < 1 | | 0% | 10 studies (10/-) | 47.5 % | low | low | high | non important | - |
| Increase AST TRAE (grade 3-4) | 1.80 [0.59, 5.47] | | < 1 | | 71% | 10 studies (10/-) | 15.0 % | low | low | high | non important | - |
| Increased ALT TRAE (grade 3-4) | 1.92 [0.65, 5.63] | | < 1 | | 80% | 10 studies (10/-) | 11.8 % | low | low | high | non important | - |
| Increased lipase level TRAE (grade 3-4) | 2.32 [1.59, 3.39] | | < 1 | | 0% | 6 studies (6/-) | 0.0 % | low | not evaluable | high | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 2.37 [0.21, 27.07] | | < 1 | | 0% | 2 studies (2/-) | 24.6 % | low | not evaluable | high | non important | - |
| Leucopenia TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.68 [0.70, 4.02] | | < 1 | | 5% | 9 studies (9/-) | 12.2 % | low | not evaluable | high | non important | - |
| Metabolism and nutrition disorders TRAE (grade 3-4) | 1.02 [0.06, 16.70] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
| Musculoskeletal and connective tissue disorders TRAE (grade 3-4) | 0.16 [0.01, 3.31] | | < 1 | | 0% | 1 study (1/-) | 87.9 % | NA | not evaluable | | non important | - |
| Myalgia TRAE (grade 3-4) | 0.91 [0.27, 3.09] | | < 1 | | 0% | 7 studies (7/-) | 56.0 % | low | not evaluable | high | non important | - |
| Myositis TRAE (grade 3-4) | 0.95 [0.10, 9.21] | | < 1 | | 0% | 3 studies (3/-) | 51.6 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 1.86 [0.70, 4.97] | | < 1 | | 0% | 8 studies (8/-) | 10.9 % | low | not evaluable | high | non important | - |
| Nephritis TRAE (grade 3-4) | 0.46 [0.04, 5.09] | | < 1 | | 0% | 2 studies (2/-) | 73.5 % | some concern | not evaluable | moderate | non important | - |
| Nervous system disorders TRAE (grade 3-4) | 1.76 [0.12, 26.45] | | < 1 | | 51% | 2 studies (2/-) | 34.3 % | low | not evaluable | high | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.95 [0.10, 9.21] | | < 1 | | 0% | 3 studies (3/-) | 51.6 % | some concern | not evaluable | moderate | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 1.50 [0.11, 19.59] | | < 1 | | 0% | 2 studies (2/-) | 38.0 % | low | not evaluable | high | non important | - |
| Pancytopenia TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.57 [0.07, 4.44] | | < 1 | | 0% | 3 studies (3/-) | 70.3 % | some concern | not evaluable | moderate | non important | - |
| Pericarditis TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 2.96 [0.30, 29.40] | | < 1 | | 0% | 2 studies (2/-) | 17.9 % | low | not evaluable | high | non important | - |
| Pneumonitis TRAE (grade 3-4) | 1.72 [0.66, 4.49] | | < 1 | | 0% | 8 studies (8/-) | 13.5 % | low | not evaluable | high | non important | - |
| Polymyalgia Rheumatica TRAE (grade 3-4) | 0.50 [0.02, 14.85] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.78 [0.18, 3.32] | | < 1 | | 0% | 7 studies (7/-) | 63.1 % | low | not evaluable | high | non important | - |
| Pruritus TRAE (grade 3-4) | 1.44 [0.60, 3.45] | | < 1 | | 0% | 10 studies (10/-) | 20.5 % | low | low | high | non important | - |
| Pyrexia TRAE (grade 3-4) | 1.48 [0.49, 4.49] | | < 1 | | 0% | 8 studies (8/-) | 24.6 % | low | not evaluable | high | non important | - |
| Rash TRAE (grade 3-4) | 1.35 [0.56, 3.28] | | < 1 | | 47% | 9 studies (9/-) | 25.1 % | low | not evaluable | high | non important | - |
| Renal and urinary disorders TRAE (grade 3-4) | 0.99 [0.08, 12.98] | | < 1 | | 0% | 2 studies (2/-) | 50.3 % | low | not evaluable | high | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 1.15 [0.22, 6.12] | | < 1 | | 23% | 4 studies (4/-) | 43.4 % | low | not evaluable | high | non important | - |
| Sarcoidosis TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 1.23 [0.32, 4.75] | | < 1 | | 74% | 5 studies (5/-) | 38.4 % | low | serious | high | non important | - |
| Stomatitis TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 2.06 [0.07, 62.55] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.59 [0.32, 7.89] | | < 1 | | 0% | 5 studies (5/-) | 28.6 % | low | serious | high | non important | - |
| Uveitis TRAE (grade 3-4) | 0.78 [0.12, 5.14] | | < 1 | | 0% | 4 studies (4/-) | 60.2 % | low | not evaluable | high | non important | - |
| Vitiligo TRAE (grade 3-4) | 0.77 [0.17, 3.50] | | < 1 | | 0% | 6 studies (6/-) | 63.4 % | low | not evaluable | high | non important | - |
